Intercell completes acquisition of Pelias

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Wien (euro adhoc) - » 100 % of Pelias shares acquired in an all-share deal;
former shareholders of Pelias receive 349,815 new Intercell shares from capital
increase
» Intercell’s product portfolio strengthened by clinical stage Pseudomonas
vaccine candidate ¬ - focus on expanding Intercell’s leading position as
technology provider and vaccine developer in the field of hospital-acquired
infections

Intercell AG (VSE; "ICLL") announced today that the acquisition of Pelias
Biomedical Development AG, Vienna (Austria) was completed with a capital
increase. 349.815 new shares, which represent about 0.9 percent of Intercell’s
current share capital, were issued to the former Pelias shareholders in return
for transferring their Pelias shares to Intercell. The transaction had been
announced in an ad-hoc statement on December 6, 2006.

The 349,815 new shares start trading at the Vienna Stock Exchange on January 17,
2006. After completion of the capital increase, Intercell’s total number of
shares issued amounts to 39,881,712.

Pelias will remain a separate legal entity operating as a subsidiary of
Intercell AG. Pelias develops products and holds certain licenses in the field
of vaccines against important pathogens involved in hospital-acquired
infections, including a clinical stage Pseudomonas vaccine candidate and a
number of antigens, which have been identified by Intercell’s proprietary
Antigen Identification Program (AIP®). Hospital-acquired infections are one of
the major causes of death and serious illness worldwide and result in an annual
burden of USD 20 billion in the developed world.

About hospital-acquired infections

Nosocomial infections - or hospital acquired infections - are bacterial or
fungal infections which are acquired in a hospital setting and cause a variety
of severe infections, many life-threatening such as pneumonia, sepsis and
bacteremia. Each year, around 2 million infections and 100,000 deaths occur in
the US alone due to nosocomial infections. The annual burden to the society is
constantly increasing due to the antibiotics resistance of the most problematic
bacteria. In the field of S. aureus infections Intercell has a strong strategic
alliance with Merck & Co., Inc. with a vaccine product in clinical trials.

About Intercell AG:

Intercell AG is a biotechnology company focused on the research, development,
manufacturing and future commercialization of innovative vaccines for the
prevention and treatment of infectious diseases, for which there exists a
substantial unaddressed medical need. Intercell develops antigens and immunizers
(adjuvants), which are derived from its proprietary technology platforms and has
in-house GMP manufacturing capability. Intercell has strategic partnerships with
a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi
Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum
Institut. Intercell has a broad development pipeline with a vaccine product
candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine
product candidate for Hepatitis C in Phase II, partnered vaccine candidates for
Tuberculosis and S. aureus, which are in Phase I, and more than five other
product candidates focused on infectious diseases in pre-clinical development.
Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For
more information please visit: www.intercell.com

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

end of announcement euro adhoc 15.01.2007 08:29:00
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
ISIN: AT0000612601
indexes:
stockmarkets: official market: Wiener Börse AG
sector: Biotechnology
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print